222720-87-8Relevant academic research and scientific papers
THERAPEUTIC INHIBITORY COMPOUNDS
-
Page/Page column 317, (2015/07/16)
The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.
TRICYCLIC PYRAZOLOPYRIDINE COMPOUNDS
-
, (2015/11/27)
In one aspect this invention relates generally to compounds of Formula I and sub-formulas thereof, or a tautomer of each thereof, a pharmaceutically acceptable salt of each thereof, or a pharmaceutically acceptable solvate of each of the foregoing, where
PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS
-
, (2015/11/25)
In one aspect this invention relates generally to compounds of Formula: and sub-formulas thereof, or a tautomer of each thereof, a pharmaceutically acceptable salt of each thereof, or a pharmaceutically acceptable solvate of each of the foregoing, where X1, L1, L3, and R3 are described herein.
HETEROCYCLIC DERIVATES
-
, (2014/12/12)
The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B,W, X, Y and Z are as defined herein.
Synthesis and structural studies of some [14]paracyclo-bis- (1,2)pyrazolium- and (1,3)imidazolium-phanes
Cabildo, Pilar,Sanz, Dionisia,Claramunt, Rosa M.,Bourne, Susan A.,Alkorta, Ibon,Elguero, Jose
, p. 2327 - 2340 (2007/10/03)
The crystal and molecular structure of [14]paracyclo-bis- (1,2)pyrazoliumphane dibromide (1a) has been determined. The compound exists in the solid state in the chair (C) conformation while both chair (C) and boat (B) conformations are present
